| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/18/2022 | 161.59% | Oppenheimer | → $5.5 | Assumes | → Outperform |
| 04/28/2022 | 137.81% | Chardan Capital | → $5 | Initiates Coverage On | → Buy |
| 06/03/2021 | 232.94% | Roth Capital | $5 → $7 | Maintains | Buy |
| 01/28/2021 | 90.25% | HC Wainwright & Co. | $3 → $4 | Maintains | Buy |
| 04/17/2020 | 42.69% | Oppenheimer | $2 → $3 | Maintains | Outperform |
| 06/27/2019 | -4.88% | Oppenheimer | → $2 | Initiates Coverage On | → Outperform |
| 10/15/2018 | 42.69% | HC Wainwright & Co. | $3 → $3 | Upgrades | Neutral → Buy |
| 03/09/2018 | — | Chardan Capital | Downgrades | Buy → Neutral | |
| 03/08/2018 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral |
Vascular Biogenics Questions & Answers
The latest price target for Vascular Biogenics (NASDAQ: VBLT) was reported by Oppenheimer on July 18, 2022. The analyst firm set a price target for $5.50 expecting VBLT to rise to within 12 months (a possible 161.59% upside). 2 analyst firms have reported ratings in the last year.
The latest analyst rating for Vascular Biogenics (NASDAQ: VBLT) was provided by Oppenheimer, and Vascular Biogenics their outperform rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vascular Biogenics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vascular Biogenics was filed on July 18, 2022 so you should expect the next rating to be made available sometime around July 18, 2023.
While ratings are subjective and will change, the latest Vascular Biogenics (VBLT) rating was a with a price target of $0.00 to $5.50. The current price Vascular Biogenics (VBLT) is trading at is $2.10, which is within the analyst's predicted range.